Status:
ACTIVE_NOT_RECRUITING
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Malignant Neoplasm of Breast
Eligibility:
All Genders
18+ years
Brief Summary
Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human e...
Eligibility Criteria
Inclusion
- Patients are eligible for the study if they were 18 years of age or older at MBC diagnosis, had HR+/HER2- confirmed and initiated first line therapy (CDK4/6i, ET, CT, or other) in the metastatic setting during the period from February 2015 through June 2022 or data cutoff.
Exclusion
Key Trial Info
Start Date :
June 24 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06495164
Start Date
June 24 2024
End Date
December 30 2026
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer New York
New York, New York, United States, 10001